- Home
- CPRX
as 04-18-2025 1:34pm EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 2.8B | IPO Year: | 2006 |
| Target Price: | $32.29 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.31 | EPS Growth: | 107.94 |
| 52 Week Low/High: | $14.47 - $26.16 | Next Earning Date: | 05-07-2025 |
| Revenue: | $491,734,000 | Revenue Growth: | 23.49% |
| Revenue Growth (this year): | 15.17% | Revenue Growth (next year): | 9.61% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | Mar 5 '25 | Sell | $21.88 | 225,000 | $4,894,609.68 | 68,873 | |
| Del Carmen Jeffrey | CPRX | Chief Commercial Officer | Mar 3 '25 | Sell | $22.89 | 30,423 | $696,382.47 | 0 | |
| Elsbernd Brian | CPRX | Chief Compliance/Legal Officer | Mar 3 '25 | Sell | $23.08 | 62,975 | $1,446,932.75 | 188,564 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
CPRX: Raising target price to $24.00
Insider Monkey
7 days ago
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?
Zacks
7 days ago
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
Simply Wall St.
9 days ago
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip
Argus Research
10 days ago
CPRX: Lowering target price to $22.00
Investor's Business Daily
10 days ago
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade
GlobeNewswire
11 days ago
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
Insider Monkey
17 days ago
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?
Compare CPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.